EFFECTS OF TOCOPHEROL AND DEPRENYL ON THE PROGRESSION OF DISABILITY IN EARLY PARKINSONS-DISEASE
EFFECTS OF TOCOPHEROL AND DEPRENYL ON THE PROGRESSION OF DISABILITY IN EARLY PARKINSONS-DISEASE
复制标题
DOI：
10.1056/nejm199301213280305
复制
发表时间：
1993-01-21
影响因子：
158.5
通讯作者：
PELUSIO, RM
中科院分区：
文献类型：
--
作者：
SHOULSON, I;FAHN, S;PELUSIO, RM
背景和方法。1987年，我们开始了一项多中心对照临床试验，研究Deprenyl（一种单胺氧化酶抑制剂）和生育酚（维生素E的一种成分，可以捕获自由基）治疗早期帕金森病。我们将800名患者随机分配到四种治疗中的一种：安慰剂，活性生育酚和丙炔苯丙胺安慰剂，活性丙炔苯丙胺和生育酚安慰剂，或两种活性药物。主要终点是残疾的发生促使临床决定开始给予左旋多巴。一项中期分析表明，丙炔苯丙胺是有益的（N Engl J Med 1989;321：136471）。我们报告了生育酚治疗后平均（+/-SD）随访14+/-6个月的结果，以及丙炔苯丙胺的随访结果。生育酚或生育酚与丙炔苯丙胺之间的任何相互作用均无有益作用。Deprenyl的有益作用主要发生在治疗的前12个月，仍然很强，并显著延迟了需要左旋多巴治疗的残疾的发生（风险比，0.50; 95%置信区间，0.41至0.62; P
Background and Methods. In 1987 we began a multicenter controlled clinical trial of deprenyl (a monoamine oxidase inhibitor) and tocopherol (a component of vitamin E that traps free radicals) in the treatment of early Parkinson's disease. We randomly assigned 800 patients to one of four treatments: placebo, active tocopherol and deprenyl placebo, active deprenyl and tocopherol placebo, or both active drugs. The primary end point was the onset of disability prompting the clinical decision to begin administering levodopa. An interim analysis showed that deprenyl was beneficial (N Engl J Med 1989;321:136471). We report the results of tocopherol treatment after a mean (+/-SD) follow-up of 14+/-6 months, as well as the follow-up results for deprenyl.Results. There was no beneficial effect of tocopherol or any interaction between tocopherol and deprenyl. The beneficial effects of deprenyl, which occurred largely during the first 12 months of treatment, remained strong and significantly delayed the onset of disability requiring levodopa therapy (hazard ratio, 0.50; 95 percent confidence interval, 0.41 to 0.62; P